Aurobindo Pharma share price
You have to be logged in to add this to Watchlist.- ₹1,133.15(-1.09%)January 23, 2026 15:55:42 PM IST
- NSE
- BSE
- Vol : 522.67 K (NSE + BSE)Last 20 day avg : 889.30 K
Aurobindo Pharma is trading -1.09% lower at Rs 1,133.15 as compared to its last closing price. Aurobindo Pharma has been trading in the price range of 1,150.00 & 1,122.45. Aurobindo Pharma has given -3.19% in this year & -2.95% in the last 5 days. Aurobindo Pharma has TTM P/E ratio 18.39 as compared to the sector P/E of 22.37.There are 26 analysts who have initiated coverage on Aurobindo Pharma. There are 9 analysts who have given it a strong buy rating & 12 analysts have given it a buy rating. 4 analysts have given the stock a sell rating.The company posted a net profit of 848.45 Crores in its last quarter.Listed peers of Aurobindo Pharma include Jagsonpal Pharmaceuticals (-0.30%), Themis Medicare (-2.89%), Neuland Laboratories (-1.85%).The Mutual Fund holding in Aurobindo Pharma was at 19.52% in 31 Dec 2025. The MF holding has increased from the last quarter. The FII holding in Aurobindo Pharma was at 13.95% in 31 Dec 2025. The FII holding has decreased from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
Updated on Jan 23, 2026, 06:45 PM UTC
- BetaLow volatility0.74Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Debt To EquityHigher than industry0.25The debt-to-equity ratio, indicating a company's financial leverage.
- Dividend YieldLower than industry0.35Annual dividends as a percentage of the stock price.
- P/BLower than historical values2.04The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
- P/EHigher than historical values19.44Price-to-earnings ratio based on trailing 12-month earnings
- PEG RatioIndicates Fair Valuation1.99The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
|
| ||||
|
| ||||
Names | Technical rating | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|---|
| Jagsonpal Pharmaceuticals | Bearish | 164.45 | -0.30 | 1,096.23 | 33.88 | 5.54 | 1.25 | 3.18 |
| Themis Medicare | Bearish | 79.00 | -2.89 | 731.23 | 31.81 | 2.35 | 0.49 | 4.62 |
| Neuland Laboratories | Bearish | 13,360.00 | -1.85 | 17,280.12 | 92.96 | 12.69 | 0.08 | 7.17 |
| Pfizer | Bearish | 4,588.20 | -2.86 | 21,016.90 | 36.12 | 5.46 | 0.69 | 1.60 |
| Unichem Laboratories | Bearish | 370.05 | -2.25 | 2,605.37 | 23.18 | 1.29 | - | 3.51 |
- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2025-11-05 | Quarterly Results |
| 2025-08-04 | Quarterly Results & Interim Dividend |
| 2025-05-26 | Audited Results |
| 2025-02-06 | Quarterly Results |
| 2024-11-09 | Quarterly Results |
- IndustryMajor Drugs
- ISININE406A01037
- BSE Code524804
- NSE CodeAUROPHARMA
Aurobindo Pharma is trading at 1133.15 as on Fri Jan 23 2026 10:25:42. This is -1.09% lower as compared to its previous closing price of 1145.60.
The market capitalization of Aurobindo Pharma is 65836.52 Cr as on Fri Jan 23 2026 10:25:42.
The average broker rating on Aurobindo Pharma is Buy. The breakup of analyst rating is given below -
- 9 analysts have given a strong buy rating
- 12 analysts have given a buy rating
- 0.00 analysts have given a hold rating
- 4 analysts have given a sell rating
- 1 analysts have given a strong sell rating
The 52 wk high for Aurobindo Pharma is 1278.00 whereas the 52 wk low is 994.35
Aurobindo Pharma can be analyzed on the following key metrics -
- TTM P/E: 18.39
- Sector P/E: 22.37
- Dividend Yield: 0.35%
- D/E ratio: 0.22
Aurobindo Pharma reported a net profit of 3485.89 Cr in 2025.
The Mutual Fund Shareholding was 19.52% at the end of 31 Dec 2025.
EQUITY QUICK LINKS
Aurobindo Pharma QUICK LINKS
FROM MARKETS
RELATED LINKS
Wait for it…
Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.